[1]
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N. Trial of Tocilizumab in Giant-Cell Arteritis. The New England journal of medicine. 2017 Jul 27:377(4):317-328. doi: 10.1056/NEJMoa1613849. Epub
[PubMed PMID: 28745999]
[2]
Brunner HI, Ruperto N, Zuber Z, Cuttica R, Keltsev V, Xavier RM, Burgos-Vargas R, Penades IC, Silverman ED, Espada G, Zavaler MF, Kimura Y, Duarte C, Job-Deslandre C, Joos R, Douglass W, Wimalasundera S, Bharucha KN, Wells C, Lovell DJ, Martini A, de Benedetti F, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. Arthritis & rheumatology (Hoboken, N.J.). 2021 Mar:73(3):530-541. doi: 10.1002/art.41528. Epub 2021 Feb 9
[PubMed PMID: 32951358]
[3]
Finzel S, Kraus S, Figueiredo CP, Regensburger A, Kocijan R, Rech J, Schett G. Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis. Annals of the rheumatic diseases. 2019 Sep:78(9):1186-1191. doi: 10.1136/annrheumdis-2018-214894. Epub 2019 May 29
[PubMed PMID: 31142474]
[4]
REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Lamontagne F, Lawler PR, Leavis HL, Linstrum KM, Litton E, Lorenzi E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Montgomery SK, Morpeth SC, Murthy S, Orr K, Parke RL, Parker JC, Patanwala AE, Pettilä V, Rademaker E, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Webb SA, Derde LPG. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. The New England journal of medicine. 2021 Apr 22:384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25
[PubMed PMID: 33631065]
[5]
Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Criner GJ, Kaplan-Lewis E, Baden R, Pandit L, Cameron ML, Garcia-Diaz J, Chávez V, Mekebeb-Reuter M, Lima de Menezes F, Shah R, González-Lara MF, Assman B, Freedman J, Mohan SV. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. The New England journal of medicine. 2021 Jan 7:384(1):20-30. doi: 10.1056/NEJMoa2030340. Epub 2020 Dec 17
[PubMed PMID: 33332779]
[6]
Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer journal (Sudbury, Mass.). 2014 Mar-Apr:20(2):119-22. doi: 10.1097/PPO.0000000000000035. Epub
[PubMed PMID: 24667956]
[7]
Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2008 Aug 1:65(15):1413-8. doi: 10.2146/ajhp070449. Epub
[PubMed PMID: 18653811]
[8]
Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harbor perspectives in biology. 2014 Sep 4:6(10):a016295. doi: 10.1101/cshperspect.a016295. Epub 2014 Sep 4
[PubMed PMID: 25190079]
Level 3 (low-level) evidence
[9]
Abdallah H, Hsu JC, Lu P, Fettner S, Zhang X, Douglass W, Bao M, Rowell L, Burmester GR, Kivitz A. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA. Journal of clinical pharmacology. 2017 Apr:57(4):459-468. doi: 10.1002/jcph.826. Epub 2016 Nov 17
[PubMed PMID: 27599663]
Level 1 (high-level) evidence
[10]
Specker C, Aringer M, Burmester GR, Killy B, Hofmann MW, Kellner H, Moosig F, Tony HP, Fliedner G. The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age. Clinical and experimental rheumatology. 2022 Sep:40(9):1657-1665. doi: 10.55563/clinexprheumatol/f7ff6q. Epub 2021 Nov 22
[PubMed PMID: 34874836]
[11]
Genovese MC, Kremer JM, van Vollenhoven RF, Alten R, Scali JJ, Kelman A, Dimonaco S, Brockwell L. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.). 2017 Sep:69(9):1751-1761. doi: 10.1002/art.40176. Epub 2017 Aug 1
[PubMed PMID: 28597609]
[12]
Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact dermatitis. 2002 Nov:47(5):312-3
[PubMed PMID: 12534540]
[13]
Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact dermatitis. 2000 Sep:43(3):172
[PubMed PMID: 10985636]
[14]
Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet (London, England). 1995 May 20:345(8960):1312-3
[PubMed PMID: 7746084]
[15]
Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986 Apr:77(4):593-7
[PubMed PMID: 3960626]
[16]
Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR. Morbidity and mortality weekly report. 1984 Apr 13:33(14):198-9
[PubMed PMID: 6423951]
[17]
Ullah S, Abid R, Haider S, Khuda F, Albadrani GM, Abdulhakim JA, Altyar AE, Abdel-Daim MM, Halimi SMA, Khalil AAK. Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19). Medicina (Kaunas, Lithuania). 2022 Aug 10:58(8):. doi: 10.3390/medicina58081076. Epub 2022 Aug 10
[PubMed PMID: 36013543]
[18]
Lima LM, Aurilio RB, Fonseca AR, Parente AAAI, Sant'Anna MFBP, Sant'Anna CC. Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review. Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo. 2023:42():e2022084. doi: 10.1590/1984-0462/2024/42/2022084. Epub 2023 Jul 10
[PubMed PMID: 37436237]